← 返回

CAR-T 细胞治疗中 T 细胞分化与耗竭的重编程

英文原题:Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.

查看英文原题

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.

PubMed 2023/10/25(内容时间) J Hematol Oncol Q1 · IF 47.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞分化是一个受到高度调控的多步骤过程,对逐步建立效应功能、免疫记忆和长期病原体控制至关重要。遇到强烈刺激(如重症或慢性感染及癌症)时,T细胞会进入低应答状态,即耗竭,导致效应功能受限。近期自体嵌合抗原受体(CAR)T细胞疗法的进展,利用T细胞生物学基本原理设计促进持久T细胞应答的产品,改变了血液系统恶性肿瘤治疗。然而,许多患者仍对治疗无应答或易复发。有关T细胞生物学的新发现,包括鉴定分化和耗竭的关键调节因子,为持久影响输注后CAR-T 细胞命运提供了新机会。新一代CAR-T 疗法及其临床实施,有望使特定患者的癌症治疗实现新的飞跃。本文综述T细胞分化和耗竭的基础原理,并介绍如何利用和靶向这些过程,进一步改进CAR-T 疗法设计与疗效。

展开英文摘要原文

T cell differentiation is a highly regulated, multi-step process necessary for the progressive establishment of effector functions, immunological memory, and long-term control of pathogens. In response to strong stimulation, as seen in severe or chronic infections or cancer, T cells acquire a state of hypo-responsiveness known as exhaustion, limiting their effector function.

Recent advances in autologous chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of hematologic malignancies by taking advantage of the basic principles of T cell biology to engineer products that promote long-lasting T cell response.

However, many patients' malignancies remain unresponsive to treatment or are prone to recur. Discoveries in T cell biology, including the identification of key regulators of differentiation and exhaustion, offer novel opportunities to have a durable impact on the fate of CAR-T cells after infusion.

Such next-generation CAR-T cell therapies and their clinical implementation may result in the next leap forward in cancer treatment for selected patients. In this context, this review summarizes the foundational principles of T cell differentiation and exhaustion and describes how they can be utilized and targeted to further improve the design and efficacy of CAR-T cell therapies.

论文信息

作者
Bulliard Y、Andersson BS、Baysal MA、Damiano J、Tsimberidou AM
第一作者单位
Appia Bio, 6160 Bristol Pkwy, Culver City, CA, 90230, USA.United States
通讯作者单位
Unit 455, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA. atsimber@mdanderson.org.United States
文献类型
综述 · 美国 NIH 资助研究 · 非美国政府资助研究
期刊
Journal of hematology & oncology2023 Oct 25
原文标识
PubMed 37880715 · DOI 10.1186/s13045-023-01504-7